(NASDAQ: AURA) Aura Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Aura Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast AURA's revenue for 2027 to be $1,273,307,640, with the lowest AURA revenue forecast at $1,273,307,640, and the highest AURA revenue forecast at $1,273,307,640. On average, 1 Wall Street analysts forecast AURA's revenue for 2028 to be $3,311,705,777, with the lowest AURA revenue forecast at $3,311,705,777, and the highest AURA revenue forecast at $3,311,705,777.
In 2029, AURA is forecast to generate $5,512,974,690 in revenue, with the lowest revenue forecast at $5,512,974,690 and the highest revenue forecast at $5,512,974,690.